Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
D Y GrahamH M El-Zimaity

Abstract

Quadruple therapy provided inadequate eradication rate when given twice-a-day at breakfast and evening meals. To test twice daily (mid-day and evening) quadruple therapy for Helicobacter pylori eradication. This was a single-centre pilot study in which H. pylori-infected (positive histology and culture and RUT) patients were given 2 x 250 mg of metronidazole and 2 x 250 mg of tetracycline, two Pepto-Bismol tablets, plus one 20 mg rabeprazole tablet twice-a-day for 14 days. H. pylori status was confirmed 4 or more weeks after the end of therapy. Thirty-seven patients including 3 with peptic ulcer disease, 19 asymptomatic infected, 4 GERD, and 11 with NUD. Mid-day quadruple therapy was successful in 92.3% (95% CI: 79-98%) including 96.2% of those with metronidazole-susceptible strains, and in 83.3% (10/12) of those with metronidazole-resistant H. pylori. Compliance was 100% by pill count except in one individual who stopped medication after 12 days because of side-effects and who failed therapy. Moderate or greater side-effects were experienced by five patients. Twice-a-day, mid-day, quadruple therapy proved effective using the combination of bismuth subsalicylate and rabeprazole instead of bismuth subcitrate and omeprazole. Deta...Continue Reading

References

May 30, 1998·British Medical Bulletin·F Mégraud
Jun 27, 2000·Gastroenterology·D Y Graham
Feb 28, 2002·Alimentary Pharmacology & Therapeutics·P MalfertheinerUNKNOWN European Helicobacter Pylori Study Group (EHPSG)
Jul 30, 2002·Alimentary Pharmacology & Therapeutics·P Della MonicaA Pera
May 20, 2003·Alimentary Pharmacology & Therapeutics·E GenéJ P Gisbert

❮ Previous
Next ❯

Citations

Feb 25, 2005·Current Infectious Disease Reports·Francis Mégraud
Jul 14, 2004·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·A ZulloS Morini
Jun 12, 2013·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·David Y GrahamMing-Shiang Wu
Jan 14, 2005·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·A ZulloD Vaira
Sep 1, 2015·Gastroenterology Clinics of North America·David Y Graham, Sun-Young Lee
Jul 5, 2007·The American Journal of Gastroenterology·William D CheyUNKNOWN Practice Parameters Committee of the American College of Gastroenterology
Sep 24, 2005·Helicobacter·Peter Bytzer, Colm O'Morain
Feb 1, 2005·Alimentary Pharmacology & Therapeutics·D Y GrahamM R Carlson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.